论文部分内容阅读
目的研究依达拉奉联合川芎嗪治疗急性脑梗死的临床疗效。方法选取2013年3月至2014年3月急性脑梗死患者86例,随机分为研究组和对照组,每组43例,研究组给予依达拉奉联合川芎嗪,对照组给予川芎嗪,比较两组临床疗效和不良反应发生。结果研究组总有效率93.3%(39/43)显著高于对照组总有效率82.2%(35/43),两组比较差异有统计学意义(P<0.05);两组不良反应比较差异未见统计学意义(P>0.05)。结论依达拉奉联合川芎嗪治疗脑梗死具有较好的临床疗效。
Objective To study the clinical efficacy of edaravone and ligustrazine in the treatment of acute cerebral infarction. Methods Eighty-six patients with acute cerebral infarction from March 2013 to March 2014 were randomly divided into study group and control group, with 43 cases in each group. The study group was given edaravone combined with ligustrazine and the control group was given ligustrazine. Two groups of clinical efficacy and adverse reactions occurred. Results The total effective rate in study group was 93.3% (39/43), which was significantly higher than that in control group (82.2%, 35/43) (P <0.05). There was no significant difference in adverse reactions between the two groups See statistical significance (P> 0.05). Conclusion Edaravone combined with ligustrazine in the treatment of cerebral infarction has a good clinical effect.